NASDAQ: PODD · Medical Devices
Insulet (PODD) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Insulet (PODD) at $158.48 a share. The stock last closed at $145.29, which puts the model's fair value 9.1% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Insulet Corp.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $152.34 to $158.48 (+4.0%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.
What the model makes of itThe price of $145.29 is 9.1% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 17 Feb 2027. Options prices imply a move of about 13% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give PODD?
The calibrated range for PODD over 63 trading days is $125.56 to $169.36. It sits around the last close, and its width comes from the volatility that PODD's own options imply (44% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $109.99 to $223.43. In 54% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Insulet Corporation develops, manufactures and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. It is listed as Insulet Corp. (PODD), in healthcare and medical devices.
Faircurve's model put the fair value at $158.48 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $152.34, so the fair value moved +4.0%. In the model's words, analysts raised their next-twelve-month EBITDA estimates, which was most of the move. The calibrated range over 63 trading days is $125.56 to $169.36. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations. The model grades the evidence as Medium. The grade reflects input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
The business scores 63 out of 100 on the model's quality measure against comparable companies. Profitability scores 100, with ROIC of 23.5% against a peer median of 8.0%. Growth quality scores 87, with trailing revenue growth of 30.7% against a peer median of 7.6%. Earnings quality scores 13, with FCF / net income of 0.61x against a peer median of 1.21x. The model compares the company with Bio-Rad Laboratories, Globus Medical, Align Technology, Bruker, Penumbra, Zimmer Biomet and Haemonetics.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does PODD report earnings, and how has the stock reacted?
Insulet's next earnings report is scheduled for 17 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 10.3% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. PODD's 30 day implied volatility works out to about 12.8% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PODD's last 8 reports, ignoring direction, was 7.5%.
What the options market has priced for a month's move in PODD
How does PODD score on business quality?
Insulet's overall quality score is 63 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 23.5%ROIC | 8.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 13 | 0.61xFCF / net income | 1.21x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 87 | 30.7%Revenue growth, trailing | 7.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 42 | 2.8%Net buybacks / market value | 1.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 52 | 0.55xNet debt / EBITDA | 0.55x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 33 | 3.7 ptsEBITDA margin downside volatility, 5y | 3.5 pts |
How does PODD compare with similar companies?
The companies in medical devices closest to Insulet in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| BIO Bio-Rad Laboratories, Inc. | $360.26 | $340.60 | -5.5% | Fairly valued |
| GMED Globus Medical, Inc. | $70.50 | $76.21 | +8.1% | Fairly valued |
| ALGN Align Technology, Inc. | $165.98 | $200.67 | +20.9% | Undervalued |
| BRKR Bruker Corporation | $60.62 | $64.27 | +6.0% | Fairly valued |
| PEN Penumbra, Inc. | $320.62 | $296.43 | -7.5% | Fairly valued |
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| HAE Haemonetics Corporation | $121.34 | $120.83 | -0.4% | Fairly valued |
What the comparable companies' multiples alone would give for PODD, the peer-implied price, is $172.59 a share on this run. The fair value weighs that against the company's own multiple.
Insulet at a glance
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
- Market value
- $10.6B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $3.6B
- Consensus revenue growth, next fiscal year
- +22.1%
- Analysts with estimates
- 14
- Beta to the US market
- 0.37
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. PODD was among them.
How the fair value is worked out: the model prices Insulet on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for PODD was $152.34. As of 14 Nov 2026 it is $158.48, a change of +4.0%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Insulet's valuation
Is Insulet stock undervalued or overvalued?
On Faircurve's model, PODD reads as Fairly valued as of 14 Nov 2026. The model's fair value is $158.48 a share against a last close of $145.29, a gap of +9.1%.
What is PODD's fair value?
$158.48 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $109.99 to $223.43.
What price range does the model give PODD?
$125.56 to $169.36 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Insulet report earnings next?
The next report is scheduled for 17 Feb 2027. Companies can move their dates.
How much has PODD moved on past earnings reports?
Across its last 8 reports the median two session move was 7.5%, ignoring direction. The largest was +17.5% around the report of 8 May 2025.
How confident is the model in this valuation?
The model's evidence grade for PODD is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on PODD
The model holds no idea open on PODD today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PODD with their outcomes. A free account is enough.